<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000653.v2.p1" parentStudy="phs000653.v2.p1" createDate="2014-03-27" modDate="2014-06-19">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Sam Berkovic, MD</td><td>University of Melbourne, Melbourne, Australia</td></tr>
		<tr><td>Principal Investigator</td><td>Patrick Cossette, MD, PhD</td><td>University of Montreal, Montreal, Canada</td></tr>
		<tr><td>Principal Investigator</td><td>Norman Delanty, MD</td><td>Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland</td></tr>
		<tr><td>Principal Investigator</td><td>Dennis Dlugos, MD</td><td>The Children&#39;s Hospital of Philadelphia, Philadelphia, PA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Evan Eichler, PhD</td><td>University of Washington, Seattle, WA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Epi4K: Gene Discovery in 4,000 Epilepsy Genomes</StudyNameEntrez>
	<StudyNameReportPage>Epi4K: Gene Discovery in 4,000 Epilepsy Genomes</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Parent-Offspring Trios</StudyType>
		<StudyType>Multiplex Families</StudyType>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Epi4K project began in 2011 as an international, multi-center study that seeks to identify and characterize the genetic bases of complex epilepsies. The Center without Walls Epi4K project includes three cores and four scientific projects, as well as a steering committee comprised of the primary study investigators and representatives from the National Institute of Neurological Disorders and Stroke (NINDS). The three cores include: (1) The Administrative Core which handles the overall coordination of Epi4K activities; (2) The Sequencing, Biostatistics and Bioinformatics Core which is responsible for generating the next-generation sequence data, inferring the genetic variation in each of the study participants, and performing the primary analyses to identify epilepsy genes; and (3) The Phenotyping and Clinical Informatics Core which verifies and archives all the phenotypic data from each study participant. The proposed number of patients to be sequenced and analyzed in the scientific projects is a minimum of 4,000; thus the Center was named "Epi4K: Gene Discovery in 4,000 Genomes".</p> <p><b>Project 1</b> addresses the genetics of rare and severe childhood epilepsies, including epileptic encephalopathies (infantile spasms and Lennox-Gastaut syndrome), and malformations of cortical development (periventricular nodular heterotopia and polymicrogyria). Exome and genome sequence data generated from DNA collected from patients will be screened for mutations (single nucleotide substitutions, small insertion-deletions, and copy number variations) that cause or contribute to the diseases. <b>Project 2</b> is focused on genetic discovery in multiplex families. This study will use next-generation sequencing to identify genomic variation that influences risk for common subtypes of epilepsy including idiopathic generalized epilepsy and nonlesional focal epilepsy. <b>Project 3</b> seeks to identify genetic determinants of prognosis in patients with a range of epilepsy disorders. This study will study established epilepsy cohorts with well-characterized data on seizure outcome to look for relationships between genetic variation and pharmacological control of seizures. <b>Project 4</b> will use next-generation sequencing data (exome and genome) to screen for epilepsy-associated copy number variation across all Epi4K projects using novel computational algorithms.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Please see individual sub-studies for detailed inclusion and exclusion criteria.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23934111"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22642626"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Epilepsy"/>
		<Disease vocab_source="MESH" vocab_term="Epileptic encephalopathy, Lennox-Gastaut type"/>
		<Disease vocab_source="MESH" vocab_term="Spasms, infantile"/>
		<Disease vocab_source="MESH" vocab_term="Periventricular Nodular Heterotopia"/>
		<Disease vocab_source="MESH" vocab_term="Epilepsy, Idiopathic Generalized"/>
		<Disease vocab_source="MESH" vocab_term="Epilepsy juvenile absence"/>
		<Disease vocab_source="MESH" vocab_term="Myoclonic Epilepsy, Juvenile"/>
		<Disease vocab_source="MESH" vocab_term="Epilepsy, Cryptogenic, Partial Complex"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Sam Berkovic, MD</AttName>
			<Institution>University of Melbourne, Melbourne, Australia</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Patrick Cossette, MD, PhD</AttName>
			<Institution>University of Montreal, Montreal, Canada</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Norman Delanty, MD</AttName>
			<Institution>Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Dennis Dlugos, MD</AttName>
			<Institution>The Children&#39;s Hospital of Philadelphia, Philadelphia, PA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Evan Eichler, PhD</AttName>
			<Institution>University of Washington, Seattle, WA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Michael Epstein, PhD</AttName>
			<Institution>Emory University, Atlanta, GA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Tracy Glauser, MD</AttName>
			<Institution>Cincinnati Children&#39;s Hospital Medical Center, Cincinnati, OH, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>David Goldstein, PhD</AttName>
			<Institution>Duke University, Durham, NC, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Erin Heinzen, PhD</AttName>
			<Institution>Duke University, Durham, NC, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Michael R. Johnson, MD, PhD</AttName>
			<Institution>Imperial College, London, England</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Ruben Kuzniecky, MD</AttName>
			<Institution>New York University, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Daniel Lowenstein, MD</AttName>
			<Institution>University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Tony Marson, MD</AttName>
			<Institution>University of Liverpool, Liverpool, England</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Heather Mefford, PhD</AttName>
			<Institution>University of Washington, Seattle, WA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Terence O&#39;Brien, MD</AttName>
			<Institution>University of Melbourne, Melbourne, Australia</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Ruth Ottman, PhD</AttName>
			<Institution>Columbia University, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Ann Poduri, MD</AttName>
			<Institution>Children&#39;s Hospital, Boston, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Ingrid Scheffer, PhD</AttName>
			<Institution>University of Melbourne, Melbourne, Australia</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Elliot Sherr, MD, PhD</AttName>
			<Institution>University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01NS077274; U01NS077276; U01NS077303; U01NS077364; U01NS077367; U01NS077275</AttName>
			<Institution>National Institutes of Health, National Institute of Neurological Diseases and Stroke, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="Epi4K" url="http://www.epgp.org/epi4k/"/>
	</StudyURLs>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NINDS</DacName>
      <DacFullName>National Institute of Neurological Disorders and Stroke</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000653.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000653.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000653.v2.p1" FileName="DUC-Epi4K_Gene_Discovery_in_4000_Epilepsy_Genomes.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
The data will be used for research purposes only and can be used to study any disease.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
